Bitcoin price today: surges to $122k, near record high on US regulatory cheer
On Tuesday, H.C. Wainwright analysts reiterated their Buy rating and maintained a $24 price target on Arvinas Inc. (NASDAQ:ARVN) stock, which currently trades at $7.33. According to InvestingPro data, analyst targets range from $8 to $110, with the stock showing a significant 9.57% return over the past week despite trading below its Fair Value. The decision follows the release of final data from the VERITAC-2 trial, which was shared by Arvinas on Saturday. The trial results indicate that vepdeg, an oral PROTAC, could become the first approved treatment for ESR1-mutant patients.
The Phase 3 trial demonstrated that vepdeg achieved a median progression-free survival of five months, compared to 2.1 months in the control group. Additionally, the treatment showcased a differentiated safety profile, enhancing its prospects for approval as a monotherapy in the second-line and later ESR1-mutant settings. InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 4.58 and holds more cash than debt on its balance sheet.
While regulatory approval appears promising, the partnership dynamics between Arvinas and Pfizer (NYSE:PFE) might evolve. Analysts suggest that the trial data could trigger a milestone payment, though co-commercialization might be less attractive due to the relatively small target patient population. Both companies are committed to bringing vepdeg to market, but future negotiations may focus on tiered royalties, additional milestone payments, or preserving Arvinas’ rights to explore combination therapy indications. With revenue growth of 498.74% in the last twelve months, Arvinas has demonstrated strong commercial potential, though InvestingPro analysts note the company is rapidly burning through cash.
Arvinas may consider allowing Pfizer to take full control of vepdeg’s commercialization for the ESR1-mutant population. This strategy would enable Arvinas to focus on advancing other assets within its portfolio. As negotiations progress in the coming weeks, the structure of the partnership could significantly influence Arvinas’ strategic direction. For deeper insights into Arvinas’s financial health and growth prospects, including 12 additional ProTips and comprehensive valuation metrics, investors can access the full analysis through InvestingPro’s detailed research report.
In other recent news, Arvinas Inc. has faced a series of downgrades and price target adjustments from multiple analyst firms following developments related to its drug vepdegestrant (vepdeg). Leerink Partners downgraded Arvinas’ stock from Outperform to Market Perform and set a price target of $9.00, citing concerns about vepdeg’s competitive position in the breast cancer treatment landscape. Similarly, Citi reduced its price target to $9.50, maintaining a Neutral rating after Pfizer decided to halt certain Phase 3 trials involving vepdeg. This decision was influenced by missed endpoints and emerging competitive data from other therapies. Truist Securities also downgraded Arvinas from Buy to Hold, lowering the price target to $11 due to a narrower than expected market for vepdeg and changes in its partnership with Pfizer. BTIG adjusted its price target to $16 from $69, maintaining a Buy rating while noting potential in Arvinas’ other programs, although these are still in early development stages. TD Cowen downgraded the stock to Hold after Pfizer canceled key combination trials, which were seen as significant market opportunities for Arvinas. These recent developments have led to a reassessment of Arvinas’ market potential and investor outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.